Vimarsana
Biggest News Aggregation in the World

Rogcon Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Rogcon Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Rogcon Inc Today - Breaking & Trending Today

Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day - Vimarsana News

Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day

Published: October 2, 2023

Positive results from preliminary analysis of PRAX-222 Part 1 showed 44% median reduction in seizures after three doses for SCN2A-gain-of-function pediatric patients Phase 3 program for...

Source: marketscreener.com
Related Topics:
United StatesMarcio SouzaAlbertoj EspayGrossman School Of MedicineRogcon IncGlobenewswire IncEuropean Medicines AgencyPraxis Precision Medicines IncDrug AdministrationExchange CommissionJoana Gardner CenterEpilepsy Study ConsortiumUniversity Of CincinnatiIonis Pharmaceutics IncPrecision MedicinesEndowed ChairDaily LivingNew Drug ApplicationMaximal Electroshock Seizure ModelOrphan Drug DesignationRare Pediatric Disease DesignationMedicines AgencyPraxi CerebrumPrivate Securities Litigation Reform ActAnnual Report
Invitae's Real-World Ciitizen Data Utilized in Praxis Precision Medicines' PRAX-222 IND Filing - Vimarsana News

Invitae's Real-World Ciitizen Data Utilized in Praxis Precision Medicines' PRAX-222 IND Filing

Published: September 20, 2022

/PRNewswire/ -- Invitae (NYSE: NVTA) and Praxis Precision Medicines, Inc. (NASDAQ: PRAX), today announced that real-world clinical insights from Invitae's...

Source: prnewswire.com
Related Topics:
United StatesAlexandra BerkInvitae CiitizenSteven PetrouRobert NussbaumAlex KaneAmy HadsockPrnewswire InvitaeDrug AdministrationExchange CommissionInvitae CorporationIonis Pharmaceutics IncRogcon IncPraxis Precision Medicines IncEuropean Medicines AgencyPraxis Precision MedicinesPraxi Investigational New DrugOrphan Drug DesignationRare Pediatric Disease DesignationIonis PharmaceuticsPrecision MedicinesPrivate Securities Litigation Reform ActQuarterly ReportAlthough PraxiPrecision Medicines Contact